Tianyu Bio-Technology603717.SHValuation Analysis

As of Oct 19, 2026, Tianyu Bio-Technology (603717.SH) trades at a negative P/E (-9.64x, due to a recent net loss), P/B of 4.90x, P/S of 2.37x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 90th percentile over the trailing 10Y window (vs. 74th percentile over 3Y); P/S sits at the 23rd percentile over the trailing 10Y window (vs. 29th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 83rd percentile within its industry and the 80th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Tianyu Bio-Technology operates in the Architecture sector. Data refreshes weekly and is for reference only, not investment advice.